Digipath
Home > Boards > US OTC > Biotechs > OncoSec Medical Inc. (ONCS)

My conversation with PUNIT DHILLON

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (12) | Next 10 | Previous | Next
zoriden Member Profile
 
Followed By 71
Posts 3,891
Boards Moderated 0
Alias Born 08/08/12
160x600 placeholder
OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019 PR Newswire (US) - 1/22/2019 8:00:00 AM
OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEY... PR Newswire (US) - 1/7/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2018 5:27:39 PM
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors PR Newswire (US) - 12/21/2018 8:30:00 AM
OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies w... PR Newswire (US) - 12/18/2018 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/17/2018 5:58:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 12/14/2018 5:09:09 PM
OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO™ + KEYTRUDA® in Refractory Metastatic Melanoma PR Newswire (US) - 12/12/2018 8:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/11/2018 5:15:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 5:10:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/11/2018 5:07:37 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 12/11/2018 5:07:37 PM
OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO™ Can Generate Productive Immune Responses In Triple Ne... PR Newswire (US) - 12/11/2018 8:30:00 AM
OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share PR Newswire (US) - 12/10/2018 8:30:00 AM
OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO™ Induces ... PR Newswire (US) - 11/29/2018 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2018 9:02:02 AM
OncoSec to Present at Piper Jaffray 30th Annual Healthcare Conference PR Newswire (US) - 11/20/2018 8:00:00 AM
OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium® PR Newswire (US) - 11/13/2018 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/9/2018 4:33:12 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/8/2018 4:47:41 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/8/2018 8:25:53 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2018 8:23:34 AM
OncoSec Appoints Robert Ward to its Board of Directors PR Newswire (US) - 11/8/2018 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/7/2018 12:09:26 PM
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial PR Newswire (US) - 11/7/2018 8:00:00 AM
zoriden   Thursday, 02/20/14 08:41:53 PM
Re: None
Post # of 46215 
My conversation with PUNIT DHILLON

ZORIDEN: First question i asked was in regards to neopulse in Europe and why it has not been mentioned in the last 3 months?

RESPONSE: There core focus is immunopulse but neopulse has had many partnership offers which they have refused do to not a huge benefit to the company and the shareholders.They want what it's worth not just to say they have a partnership.There is a few companies that are more lining up with what ONCS would like but details can not be given, and no deal has been inked yet!

What he really expounded upon and what has me so excited was the fact he knows what they have and they are not going to take less than what it's worth

ZORIDEN: This was more of what i asked of him and if he would like to elaborate on.I said that with the core group of investors and more and more coming in, with all the catalysts we have in 2014. Give us the year to organically grow the share structure and not utilize a R/S..

RESPONSE: As of now that is not even a thought the stock is moving on it's own and this is a big year for Oncosec.One of the big things he learned from INO when he did a R/S was the aftermath.And the only reason he would do a R/S is if the stock was not moving and only to uplist but that will not happen for unless things change.He agreed that the organic way was the best way but if need be they would consider it.


ZORIDEN: In regards to IL-12 with INO and the Pfizer electroporation deal with the San Diego company.

RESPONSE: INO uses IL-12 as a vaccine in the muscle they can not use it in tumors only ONCS can.He stated that anyone wanting to use IL-12 in combination with tumors will have to go through ONCS..In regards to Pfizer he chuckled.He stated INO and ONCS have the best electroporation out there and Pfizer was looking for a lower price cheaper alternative.With a back door kind of method.Day late and a dollar short.

ZORIDEN: MERKEL cell melanoma do you get granted or do you have to file for orphan status?

RESPONSE: You have to file for it but there is no point now because the FDA will want to see the MCC stage 2 trials.So once that is done the filing will happen.

Zoriden: Would you be surprised if you do not have a partner by the end of 2014?

RESPONSE: YES, there is interest in possible funding for our stage 3's again they will not just take a partnership for the sake of a partnership nothing is set in stone. Don't any one go saying they will have a partner.The trials still have to be good.They are going to get the most of "THE GOLDEN EGGS they are sitting on".They are in the research field so the partner they do join forces with will be the ones bringing there (ONCS) drugs to market.Oncosec at this time is not equiped to market drugs.


ZORIDEN: Do you see you selling this company?Or bringing it to market?

RESPONSE: WE would like to see it go to market but we can't say we would not accept a buyout. But that number we have not even thought of.But he Alluded it to being alot.


ZORIDEN: Where do you see ONCOSEC in the next 2-5 years?


RESPONSE: Well we are growing quickly we are in the process of hiring 10 more people we have doubled in size in under 2 years.I see us having a drug FDA approved and commercialized.We are sitting on 3 Golden eggs and we are not stopping there.We will have another drug in trials by years end and more to come in following years with the potential of using other drugs in combination.We are at the forefront of immunotherapy and we have a platform that we can continue to expand upon.We have DR. Robert Pierce who was looking for what would work to turn the human body to accept PD-1s and he found it here with ONCOSEC and if he see's what we have and we will use that as leverage with a partnership.


This was our conversation not word for word but close so don"t assume, expect, or over estimate that all things can change.This was the jist of our conversation and i am very pleased i was able to speak with him...Most of this was from memory and as close as i can recall. No names no dates no forward looking statements were given other than potentials...Thanks I am very excited with our future here! $ONCS





My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (12) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist